I'm Dipping a Toe in Invitae
A close above $18 would go a long way towards making breakout buyers feel better.
Arcturus Therapeutics Has a Candidate for a Covid-19 Vaccine
When I first started buying ARCT shares I didn't conceive of a valuation of $1 billion, but I also didn't conceive of the global impact of a pandemic.
How to Play Emergent Biosolutions' Continuing Rally
Let's check out the latest charts and indicators.
Quidel Stock Is Finally Correcting: What to Do Now
The stock has formed a bearish engulfing pattern.
A Trio of Back-to-Normality Trades Worth Noting
With lockdowns ending and life as we knew it resuming to some extent, these three stocks should benefit.
Cannabis Cos. Ready for Sales to Heat Back Up in Massachusetts
State's dispensaries get OK to reopen recreational curbside service on May 25.
2 Lackluster Names Insiders Are Buying
Bausch Health and Greenbrier Cos. have seen large chunks of their shares bought recently by people close to the companies.
Johnson & Johnson Is Pulling Back to Retest its Breakout Zone
The broad market may be soft for another week but if I find more stocks in a similar position as JNJ I won't see a reason to join the bear camp.
Let's Unmask This Opportunity
The big push for Alpha Pro Tech has been N95 masks, which we know are in huge demand, and here's a trade in the name right now.
Vaccine Maker Novavax Shares Have Soared but Can It Continue?
The company has worked on two previous coronavirus vaccines as well as an Ebola vaccine.